The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension

Detalles Bibliográficos
Autores principales: Forzano, Imma, Mone, Pasquale, Varzideh, Fahimeh, Jankauskas, Stanislovas S., Kansakar, Urna, De Luca, Antonio, Santulli, Gaetano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780529/
https://www.ncbi.nlm.nih.gov/pubmed/36568122
http://dx.doi.org/10.3389/fendo.2022.1097968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780529/
https://www.ncbi.nlm.nih.gov/pubmed/36568122
http://dx.doi.org/10.3389/fendo.2022.1097968

Ejemplares similares